Phosphorylated Neurofilament Heavy Chain Correlations to Visual Function, Optical Coherence Tomography, and Treatment

Table 2

Visual and clinical scores by treatment group and OCT.

Treatment group	IVMP		Placebo		Prednisone		Total		Total
OCT at 15 yrs	Yes	No	Yes	No	Yes	No	Yes	No	Total
N	18	45	15	34	18	45	51	124	175
Mean ± SD LogMAR acuity
Affected eye
Baseline	0.78 ± 0.65	0.66 ± 0.63	0.59 ± 0.71	0.67 ± 0.72	0.86 ± 0.67	0.86 ± 0.69	0.75 ± 0.67	0.74 ± 0.68	0.74 ± 0.68
Year 5	−0.08 ± 0.14	−0.06 ± 0.15	−0.05 ± 0.11	−0.02 ± 0.37	−0.07 ± 0.16	0.01 ± 0.32	−0.07 ± 0.14	−0.03 ± 0.29	−0.04 ± 0.25
Year 10	−0.08 ± 0.10	0.01 ± 0.35	−0.03 ± 0.09	−0.07 ± 0.25	−0.07 ± 0.11	0.06 ± 0.37	−0.06 ± 0.10	0.01 ± 0.33	−0.01 ± 0.28
Year 15	−0.07 ± 0.11	0.06 ± 0.38	−0.02 ± 0.10	0.04 ± 0.28	−0.06 ± 0.10	0.11 ± 0.36	−0.05 ± 0.11	0.07 ± 0.34	0.03 ± 0.29
Fellow eye
Baseline	−0.12 ± 0.07	−0.12 ± 0.09	−0.13 ± 0.10	−0.08 ± 0.22	−0.14 ± 0.08	−0.14 ± 0.09	−0.13 ± 0.08	−0.12 ± 0.14	−0.12 ± 0.12
Year 5	−0.14 ± 0.14	−0.12 ± 0.11	−0.11 ± 0.10	−0.08 ± 0.32	−0.17 ± 0.09	−0.07 ± 0.30	−0.14 ± 0.12	−0.09 ± 0.26	−0.11 ± 0.22
Year 10	−0.10 ± 0.15	−0.07 ± 0.21	−0.07 ± 0.11	−0.15 ± 0.09	−0.15 ± 0.08	−0.05 ± 0.29	−0.11 ± 0.12	−0.08 ± 0.22	−0.09 ± 0.19
Year 15	−0.10 ± 0.15	0.01 ± 0.30	−0.09 ± 0.09	−0.04 ± 0.12	−0.12 ± 0.09	−0.01 ± 0.32	−0.10 ± 0.11	−0.01 ± 0.27	−0.05 ± 0.23
Mean ± SD contrast sensitivity
Affected eye
Baseline	7.8 ± 4.8	8.1 ± 4.6	8.6 ± 5.6	7.6 ± 5.1	7.4 ± 5.4	7.0 ± 4.9	7.9 ± 5.2	7.5 ± 4.8	7.6 ± 4.9
Year 5	14.3 ± 1.3	14.0 ± 1.5	13.9 ± 1.5	13.8 ± 2.8	14.8 ± 0.9	13.3 ± 3.0	14.4 ± 1.3	13.7 ± 2.5	13.9 ± 2.2
Year 10	11.6 ± 0.9	11.4 ± 2.2	11.3 ± 1.3	11.4 ± 2.4	11.8 ± 1.0	10.9 ± 2.5	11.6 ± 1.1	11.2 ± 2.4	11.3 ± 2.0
Year 15	11.6 ± 1.1	11.1 ± 2.7	11.3 ± 1.3	11.2 ± 2.7	11.5 ± 1.5	10.8 ± 2.9	11.5 ± 1.3	11.0 ± 2.8	11.2 ± 2.3
Fellow eye
Baseline	15.2 ± 0.7	15.6 ± 0.6	14.9 ± 0.6	15.0 ± 1.3	15.4 ± 0.6	15.3 ± 0.8	15.2 ± 0.7	15.3 ± 0.9	15.3 ± 0.9
Year 5	15.3 ± 1.0	15.2 ± 0.7	15.1 ± 0.5	14.8 ± 2.1	15.7 ± 0.5	14.7 ± 2.6	15.4 ± 0.7	14.9 ± 2.0	15.1 ± 1.7
Year 10	12.2 ± 1.4	12.0 ± 1.2	12.3 ± 0.5	12.2 ± 0.9	12.2 ± 0.6	11.7 ± 2.3	12.3 ± 0.9	11.9 ± 1.6	12.0 ± 1.4
Year 15	12.1 ± 1.5	11.8 ± 1.8	12.5 ± 0.8	12.1 ± 1.0	12.5 ± 0.7	11.5 ± 2.7	12.4 ± 1.1	11.8 ± 2.0	12.0 ± 1.7
Mean ± SD mean deviation
Affected eye
Baseline	−22.0 ± 11.3	−21.5 ± 9.9	−19.2 ± 10.6	−21.6 ± 10.0	−23.4 ± 11.2	−23.7 ± 10.2	−21.7 ± 11.0	−22.3 ± 10.0	−22.1 ± 10.3
Year 5	−2.0 ± 2.1	−1.3 ± 4.0	−5.1 ± 7.9	−3.0 ± 8.1	−1.5 ± 2.6	−3.9 ± 7.4	−2.7 ± 4.9	−2.7 ± 6.6	−2.7 ± 6.2
Year 10	−1.3 ± 2.8	−2.5 ± 5.1	−5.0 ± 7.6	−3.0 ± 6.9	−1.5 ± 1.8	−4.1 ± 7.3	−2.5 ± 4.8	−3.3 ± 6.5	−3.0 ± 6.0
Year 15	−1.0 ± 1.9	−1.7 ± 5.7	−5.1 ± 7.2	−2.9 ± 6.9	−1.6 ± 2.1	−3.8 ± 6.6	−2.4 ± 4.5	−2.8 ± 6.4	−2.7 ± 5.7
Fellow eye
Baseline	−2.1 ± 1.9	−2.8 ± 1.9	−2.7 ± 2.3	−3.3 ± 3.5	−3.6 ± 2.5	−3.8 ± 4.6	−2.8 ± 2.3	−3.3 ± 3.5	−3.1 ± 3.2
Year 5	−1.1 ± 2.3	−0.6 ± 1.9	−1.8 ± 5.3	−1.1 ± 5.1	−0.1 ± 2.4	−2.5 ± 6.5	−1.0 ± 3.5	−1.4 ± 4.9	−1.3 ± 4.5
Year 10	−0.7 ± 2.7	−1.7 ± 4.6	−1.7 ± 4.9	−1.2 ± 2.7	0.0 ± 1.2	−2.3 ± 7.1	−0.8 ± 3.2	−1.8 ± 5.3	−1.5 ± 4.8
Year 15	−0.3 ± 2.9	−1.3 ± 5.5	−2.0 ± 5.2	−0.7 ± 2.4	−0.2 ± 1.7	−2.6 ± 5.0	−0.8 ± 3.5	−1.6 ± 4.6	−1.3 ± 4.2
𝑁 (%) diagnosed with multiple sclerosis
Baseline	0	3 (7%)	1 (7%)	4 (12%)	1 (6%)	8 (18%)	2 (4%)	15 (12%)	17 (10%)
Year 5	4 (22%)	14 (31%)	3 (20%)	20 (59%)	3 (20%)	6 (33%)	13 (26%)	59 (48%)	72 (41%)
Year 10	5 (28%)	17 (38%)	5 (33%)	23 (68%)	6 (33%)	30 (67%)	16 (31%)	70 (57%)	86 (49%)
Year 15	6 (33%)	20 (44%)	7 (47%)	23 (68%)	7 (39%)	32 (71%)	20 (39%)	75 (61%)	95 (54%)